#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14618	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2170	665.6	0	.	n	.	0	C1122T	SNP	1122	1122	C	1368	1368	T	810	T,C	565,225	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14618	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2170	665.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1696	1696	T	737	T,C	712,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14618	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2170	665.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1430	1430	C	813	C,T,G	805,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27008	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3513	762.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1625	1625	A	870	A,G	854,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27008	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3513	762.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2259	2259	C	829	C	808	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27008	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3513	762.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2333	2333	A	846	A	837	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27008	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3513	762.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2885	2885	C	831	C,A	817,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2002	folP	855	855	100.0	folP.l15.c4.ctg.1	1511	131.6	1	SNP	p	R229S	1	.	.	685	687	AGC	984	986	AGC	195;193;194	A;G;C	191;187;186	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5854	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3596	161.7	1	SNP	p	S91F	1	.	.	271	273	TTC	700	702	TTC	198;197;197	T;T;C	197;197;196	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5854	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3596	161.7	1	SNP	p	D95G	1	.	.	283	285	GGC	712	714	GGC	188;190;190	G;G;C	187;188;190	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5854	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3596	161.7	1	SNP	p	G95N	0	.	.	283	285	GGC	712	714	GGC	188;190;190	G;G;C	187;188;190	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1826	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1329	136.1	1	SNP	p	G45D	0	.	.	133	135	GGC	484	486	GGC	223;223;222	G,C;G;C	217,1;216;217	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	910	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1090	83.1	0	.	n	.	0	A197.	DEL	197	197	A	655	655	A	207	A	205	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4896	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2979	163.1	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1454	1456	GTC	209;207;205	G,T;T;C	205,1;199;201	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4896	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2979	163.1	1	SNP	p	D86N	0	.	.	256	258	GAC	560	562	GAC	187;184;185	G;A;C	184;172;180	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4896	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2979	163.1	1	SNP	p	R87I	0	.	.	259	261	CGT	563	565	CGT	185;181;185	C;G;T	182;178;178	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4896	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2979	163.1	1	SNP	p	R87W	0	.	.	259	261	CGT	563	565	CGT	185;181;185	C;G;T	182;178;178	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4896	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2979	163.1	1	SNP	p	S87R	1	.	.	259	261	CGT	563	565	CGT	185;181;185	C;G;T	182;178;178	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4896	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2979	163.1	1	SNP	p	S88P	0	.	.	262	264	TCC	566	568	TCC	184;184;185	T;C;C	178;178;182	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4394	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2686	161.9	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1359	1361	TGC	190;190;193	T,C;G;C,T	183,1;183;190,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4394	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2686	161.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1569	1571	GGC	219;217;214	G;G;C	215;213;209	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1331	1333	GCA	202;203;204	G;C;A	201;194;203	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1334	1336	ATC	204;205;206	A;T;C	198;203;204	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1346	1348	GTG	200;200;199	G;T;G	197;195;193	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1346	1348	GTG	200;200;199	G;T;G	197;195;193	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1850	1852	ACC	167;168;169	A,G,C;C,A;C	159,1,1;166,1;165	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1904	1906	GCG	153;154;156	G;C;G	145;137;145	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1904	1906	GCG	153;154;156	G;C;G	145;137;145	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2027	2029	GGC	110;110;111	G;G;C	108;109;109	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2036	2038	GGC	110;107;106	G;G;C	104;103;103	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2466	156.0	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2054	2056	TCG	90;90;90	T,G;C,G;G,C	62,12;75,1;79,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5600	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3118	178.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1642	1644	CCG	212;212;211	C;C,T;G	199;207,1;202	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2508	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1895	130.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	591	591	C	165	C,G	153,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	515	517	GGA	204;201;208	G,C;G;A	200,1;197;204	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	T87A	NONSYN	259	261	ACT	632	634	GCT	181;178;179	G;C;T	178;177;174	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	T89S	NONSYN	265	267	ACC	638	640	AGC	175;173;174	A;G;C,A	170;169;171,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	K120D	NONSYN	358	360	AAG	731	733	GAC	183;180;181	G;A,G;C,T	178;173,1;179,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	N124G	NONSYN	370	372	AAT	743	745	GGT	180;180;180	G,A;G,A;T,G	177,1;175,1;171,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	E137K	NONSYN	409	411	GAA	782	784	AAA	182;182;184	A,G;A;A	180,1;180;182	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	800	802	CAA	180;177;180	C;A;A	179;176;177	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	824	826	GCA	181;183;184	G;C;A	178;181;177	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1130	1132	CAA	201;201;202	C;A;A	200;200;201	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	.	INDELS	760	761	AC	1134	1137	ATCA	203;205;208;210	A;T;C;A	201;202;208;208	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	.	INDELS	763	764	TG	1141	1143	AGT	213;214;213	A;G;T,A	213;213;209,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1148	1150	GAT	219;221;225	G;A;T	215;218;222	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1256	1258	AGT	209;205;200	A,G;G,A;T	206,1;198,1;194	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2606	porB1b	1041	1041	97.33	porB1b.l6.c4.ctg.1	1668	155.4	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1262	1264	GAC	192;192;192	G,A,C;A;C	183,1,1;186;190	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9776	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4818	201.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1986	1988	CAT	224;222;223	C;A;T	219;218;219	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1174	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1114	104.5	1	SNP	p	V57M	1	.	.	169	171	ATG	525	527	ATG	241;242;241	A;T;G	239;242;241	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
